glp 1 masld Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease Main therapeutic approaches for MASLD.

One thing is that, in trials, some of these new medications are increasing the amount of weight loss, but that means higher reward, higher risk, with more side effects, says John Morton, MD, MPH, chief of Yale Medicine Bariatric and Minimally Invasive Surgery and a board-certified obesity medicine specialist

Together, well create a safe, effective plan designed just for you

If you delivered via cesarean, your body is healing from major abdominal surgery

Large-scale trials comparing GLP-1 agonists alone to traditional treatments do not yet exist

Stand on band, hold handles at sides

Developing a national nutrition policy strategy to advance cardiometabolic health and health equity